{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:00Z","timestamp":1791894180349,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3150,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s13311-014-0305-y","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T12:13:36Z","timestamp":1411647216000},"page":"234-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and NaV Blocker, is a Potent Novel Anticonvulsant"],"prefix":"10.1016","volume":"12","author":[{"given":"Nichole","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Paul","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zolkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Je","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Rogawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac N.","family":"Pessah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-014-0305-y_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-014-0305-y_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)","volume":"103","author":"Bialer","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0305-y_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1124\/mol.107.043216","article-title":"N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A novel, selective KCNQ2\/Q3 potassium channel activator","volume":"73","author":"Wickenden","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/jpet.108.137794","article-title":"In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2\/Q3 (Kv7.2\/Kv7.3) activator in rodent anticonvulsant models","volume":"326","author":"Roeloffs","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0305-y_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2013.03.039","article-title":"Characterization of a novel high-potency positive modulator of K(v)7 channels","volume":"709","author":"Dalby-Brown","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.279.5349.403","article-title":"A potassium channel mutation in neonatal human epilepsy","volume":"279","author":"Biervert","year":"1998","journal-title":"Science"},{"key":"10.1007\/s13311-014-0305-y_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0028-3908(85)90011-5","article-title":"2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties","volume":"24","author":"Mizoule","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0305-y_bib8","doi-asserted-by":"crossref","unstructured":"Rogawski MA. Epilepsy. In: Neurotherapeutics: Emerging Strategies Edited by Pullan L, Patel J. Totowa, NJ: Humana Press; 1996;193-273.","DOI":"10.1007\/978-1-59259-466-5_6"},{"key":"10.1007\/s13311-014-0305-y_bib9","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1517\/14656566.2013.819344","article-title":"New therapy options for amyotrophic lateral sclerosis","volume":"14","author":"Gordon","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-014-0305-y_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(24)36856-9","article-title":"Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels","volume":"282","author":"Song","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0305-y_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0028-3908(01)00028-4","article-title":"Pharmacological modulation of SK3 channels","volume":"40","author":"Grunnet","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0305-y_bib12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0026-895X(24)26499-3","article-title":"The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK","volume":"57","author":"Duprat","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mol.108.051425","article-title":"Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure","volume":"75","author":"Sankaranarayanan","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-physiol-020911-153336","article-title":"Small-conductance Ca2+-activated K+ channels: form and function","volume":"74","author":"Adelman","year":"2012","journal-title":"Ann Rev Physiol"},{"key":"10.1007\/s13311-014-0305-y_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2174\/092986707780831186","article-title":"Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications","volume":"14","author":"Wulff","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1007\/s13311-014-0305-y_bib16","series-title":"Antiepileptic drugs","first-page":"36","article-title":"Discovery and preclinical development of antiepileptic drugs","author":"White","year":"2002"},{"key":"10.1007\/s13311-014-0305-y_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0022-3565(25)22531-9","article-title":"Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation","volume":"270","author":"Kokate","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0305-y_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.117.3037.283","article-title":"Development of strains of albino mice with predictable susceptibilities to audiogenic seizures","volume":"117","author":"Frings","year":"1953","journal-title":"Science"},{"key":"10.1007\/s13311-014-0305-y_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/toxsci\/kfs244","article-title":"Tetramethylenedisulfotetramine alters Ca2+ dynamics in cultured hippocampal neurons: mitigation by NMDA receptor blockade and GABA(A) receptor-positive modulation","volume":"130","author":"Cao","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1007\/s13311-014-0305-y_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0305-y_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.yebeh.2004.08.021","article-title":"Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels","volume":"5","author":"Bialer","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-014-0305-y_bib22","doi-asserted-by":"crossref","first-page":"13525","DOI":"10.1073\/pnas.0705924104","article-title":"TRPA1 mediates formalin-induced pain","volume":"104","author":"McNamara","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-014-0305-y_bib23","doi-asserted-by":"crossref","first-page":"41404","DOI":"10.1074\/jbc.M509610200","article-title":"Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of hippocampal pyramidal neurons","volume":"280","author":"Pedarzani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0305-y_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/B978-0-444-52899-5.00021-6","article-title":"Mechanisms of action of antiseizure drugs","volume":"108","author":"Porter","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-014-0305-y_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1074","article-title":"The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions","volume":"10","author":"Rogawski","year":"2004","journal-title":"Nat Med"},{"key":"10.1007\/s13311-014-0305-y_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-014-0305-y_bib27","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI25466","article-title":"Sodium channel mutations in epilepsy and other neurological disorders","volume":"115","author":"Meisler","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-014-0305-y_bib28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/j.1460-2075.1982.tb01293.x","article-title":"The Ca2+-dependent slow K+ conductance in cultured rat muscle cells: characterization with apamin","volume":"1","author":"Hugues","year":"1982","journal-title":"EMBO J"},{"key":"10.1007\/s13311-014-0305-y_bib29","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.273.5282.1709","article-title":"Small-conductance, calcium-activated potassium channels from mammalian brain","volume":"273","author":"Kohler","year":"1996","journal-title":"Science"},{"key":"10.1007\/s13311-014-0305-y_bib30","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1073\/pnas.96.8.4662","article-title":"An apamin-sensitive Ca2+-activated K+ current in hippocampal pyramidal neurons","volume":"96","author":"Stocker","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-014-0305-y_bib31","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1523\/JNEUROSCI.0380-04.2004","article-title":"SKCa channels mediate the medium but not the slow calcium-activated afterhyperpolarization in cortical neurons","volume":"24","author":"Villalobos","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0305-y_bib32","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1523\/JNEUROSCI.0182-04.2004","article-title":"Small conductance Ca2+-activated K+ channel knock-out mice reveal the identity of calcium-dependent afterhyperpolarization currents","volume":"24","author":"Bond","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0305-y_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/jphysiol.2002.027854","article-title":"Distinct contributions of small and large conductance Ca2+-activated K + channels to rat Purkinje neuron function","volume":"548","author":"Edgerton","year":"2003","journal-title":"J Physiol"},{"key":"10.1007\/s13311-014-0305-y_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-2999(90)90339-8","article-title":"Effects of apamin and nicotinic acetylcholine receptor antagonists on inferior collicular seizures","volume":"187","author":"McCown","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib35","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1074\/jbc.M010001200","article-title":"Control of electrical activity in central neurons by modulating the gating of small conductance Ca2+-activated K+ channels","volume":"276","author":"Pedarzani","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0305-y_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1254\/jphs.08214FP","article-title":"K+-channel openers suppress epileptiform activities induced by 4-aminopyridine in cultured rat hippocampal neurons","volume":"108","author":"Kobayashi","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1007\/s13311-014-0305-y_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nn1648","article-title":"Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia","volume":"9","author":"Walter","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-014-0305-y_bib38","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1523\/JNEUROSCI.6341-09.2010","article-title":"KCa channels as therapeutic targets in episodic ataxia type-2","volume":"30","author":"Alvina","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0305-y_bib39","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI200420216","article-title":"Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia","volume":"113","author":"Shakkottai","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-014-0305-y_bib40","doi-asserted-by":"crossref","first-page":"13002","DOI":"10.1523\/JNEUROSCI.2789-11.2011","article-title":"do Carmo Costa M, Dell'Orco JM, et al. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3","volume":"31","author":"Shakkottai","year":"2011","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0305-y_bib41","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chembiol.2012.07.013","article-title":"Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2","volume":"19","author":"Kasumu","year":"2012","journal-title":"Chem Biol"},{"key":"10.1007\/s13311-014-0305-y_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0920-1211(95)00040-2","article-title":"Evidence for decreased calcium dependent potassium conductance in hippocampal CA3 neurons of genetically epilepsy-prone rats","volume":"22","author":"Verma-Ahuja","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0305-y_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.brainres.2009.02.034","article-title":"Protein expression of small conductance calcium-activated potassium channels is altered in inferior colliculus neurons of the genetically epilepsy-prone rat","volume":"1270","author":"N'Gouemo","year":"2009","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0305-y_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nbd.2011.08.019","article-title":"Network excitability in a model of chronic temporal lobe epilepsy critically depends on SK channel-mediated AHP currents","volume":"45","author":"Schulz","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0305-y_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2006.07.007","article-title":"In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant","volume":"546","author":"Anderson","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-014-0305-y_bib46","doi-asserted-by":"crossref","first-page":"17534","DOI":"10.1073\/pnas.1306285110","article-title":"Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-014-0305-y_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0305-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-014-0305-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300867X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300867X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0305-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:46:05Z","timestamp":1761806765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300867X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S187874792300867X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-014-0305-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and NaV Blocker, is a Potent Novel Anticonvulsant","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-014-0305-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}